BREAKING: Gold Prices, Stocks Continue To SlideBoston Scientific (BSX) stock rose early Wednesday after the medical products giant reported adjusted earnings of 75 cents per share on $5.07 billion in third-quarter sales.On average, analysts polled by FactSet expected Boston Sci to earn 71 cents per share and report $4.97 billion in sales.During the year-earlier period, the company earned 63 cents a share and had $4.21 billion in sales.For the year, Boston Scientific guided to 20% sales growth on a strict, a ...

Boston Scientific (BSX) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5.63%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $0.72 per share when it actually produced earnings of $0.75, delivering a surprise of +4.17%.Over the last four q ...

Safe Harbor for Forward-Looking Statements and Use of Document Safe Harbor for forward-looking statements: This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions ...

Boston Scientific raised its annual profit forecast on Wednesday, after the medical device maker beat third-quarter profit estimates on strong demand for its heart devices. ...

Core Viewpoint - The article discusses the concept of the "Death Cross" as a bearish signal in stock trading, indicating a potential trend shift and the need for investors to be cautious about their positions in certain stocks. Group 1: Death Cross Overview - The Death Cross occurs when a stock's 50-day moving average falls below its 200-day moving average, signaling weakening short-term momentum and a possible trend shift [2][3] - This indicator is recognized by traders across various timelines and investment goals, serving as a signal to take profits or enter short positions [3] - Historical data shows that Death Crosses on major indices like the S&P 500 have preceded long-term bear markets in 2000, 2007, and 2022 [3] Group 2: Company Analysis - Boston Scientific - Boston Scientific has a current stock price of $99.88, with a P/E ratio of 59.45 and a price target of $121.61 [6] - The company reported a 22% year-over-year sales growth in Q2 2025, but the stock has declined 3% over the last three months, indicating market indifference to its performance [7] - The stock has formed a Death Cross, breaking through key support levels, and faces fundamental challenges due to its high valuation, trading at nearly 60x earnings [9] Group 3: Company Analysis - Darden Restaurants - Darden Restaurants, with a stock price of $187.67 and a P/E ratio of 20.11, operates popular chains like Olive Garden and Longhorn Steakhouse [10] - The company is experiencing pressure from rising labor and input costs, which is affecting its competitive pricing in the full-service casual dining segment [11] - DRI shares have broken through the 50-day SMA support level, indicating a loss of upward momentum, and may continue to struggle unless the restaurant industry improves [13] Group 4: Company Analysis - Stryker - Stryker's stock is priced at $379.96, with a P/E ratio of 50.33 and a price target of $431.76 [14] - Despite consistent earnings beats, the stock has only increased 3% in the last 12 months due to reliance on elective procedures and exposure to macroeconomic trends [15] - A Death Cross is forming for Stryker as it approaches the 200-day SMA, suggesting potential further downside if the price is rejected at this level [17]

The medical device company recorded higher third-quarter sales and raised its full-year earnings guidance on the back of continued growth in its cardiovascular segment. ...

FOR IMMEDIATE RELEASE Boston Scientific announces results for third quarter 2025 Marlborough, Mass. (October 22, 2025) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported basis, 19.4 percent on an operational basis and 15.3 percent on an organic basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $755 million or $0.51 per ...

Accessibility StatementSkip Navigation MARLBOROUGH, Mass., Oct. 22, 2025 /PRNewswire/ --Â Boston Scientific Corporation (NYSE:Â BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported basis, 19.4 percent on an operational basis and 15.3 percent on an organic basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $755 million or $0.51 per share (EPS), compared to $469 m ...

行业评级：看好（维持） 证券研究报告|行业专题报告 医药生物 2025年10月21日 波士顿科学专题报告系列二之电生理&左心耳封堵篇： --电生理弯道超车，左心耳封堵引领市场 证券分析师 姓名：刘闯 资格编号：S1350524030002 邮箱：liuchuang@huayuanstock.com 联系人 姓名：梁裕 邮箱：liangyu@huayuanstock.com 请务必仔细阅读正文之后的评级说明和重要声明 报告要点 2 ◼ 波士顿科学：快速增长的头部平台型器械公司。波士顿科学为全球头部的医疗器械平台公司，历经40余年发展，形成如今的电生理、左心耳封 堵、心脏介入、外周介入、心律管理、内窥镜、泌尿及神经调节八大板块，2025年各赛道合计市场规模预计达700亿美元。公司在多个板块均 处于领先地位，其中在左心耳封堵、内窥镜、泌尿/女性健康等领域均保有较多份额。同时，由于电生理业务2024年开始快速增长，市场份额 有望实现较大提升。 ◼ 当前最大增长引擎来自电生理及左心耳封堵业务 ◼ 电生理：凭借颠覆式技术迅速弯道超车，收入增速大幅高于公司整体。脉冲电场消融（PFA）凭借优异的临床数据、更优的术者体验以及 ...

Core Insights - Boston Scientific Corporation (NYSE:BSX) is recognized as one of the top medical device stocks to invest in, with TD Cowen reaffirming a Buy rating and a price target of $115 on October 10 [1] - The recent analyst visit to Boston Scientific's headquarters reinforced confidence in the company's outlook, particularly in the context of its latest investor day [1] Group 1: Company Performance and Outlook - Significant advancements were noted in pulsed field ablation (PFA) technology during the analyst visit, with feedback suggesting a "very compelling" outlook for Boston Scientific despite increasing market competition [2] - CEO Mike Mahoney provided thoughtful responses to growth-related inquiries, emphasizing category leadership as a strategy for achieving success in the market [2] Group 2: Company Profile - Boston Scientific Corporation is a global leader in manufacturing medical devices, including stents, brain stimulation systems, heart monitors, and catheters [3]